Molecule intelOpportunity: ModerateEssential

Apixaban

53 brands · 21 companies · product forms

ATC: B01AF02

Opportunity snapshot

Launch attractiveness
43
Market saturation
60
Price room
100
Regulatory risk
0
53
brands
21
companies
Rs 3,440.65
median price
70
price points
19.8x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 11%

Price room

Across observed sources and strengths
CheapestRs 221.7
MedianRs 3,440.65
Most expensiveRs 4,390.35
Spread19.8×
Sources: DRAP-official, DVAGO

max/min price ratio 19.80x across 70 trusted points (Rs 221.7-4390.35). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Apixaban — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(40) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

21 canonical companies and 53 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 19.80x across 70 trusted points (Rs 221.7-4390.35). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.